Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25230181 | 1.00 | OPRD1 (0.40) | OPRD1TLR2KMT2APTPN1 | |
| SCHEMBL25944308 | 1.00 | OPRD1 (0.40) | OPRD1TLR2KMT2APTPN1 | |
| SCHEMBL31584331 | 0.89 | KMT2A (0.39) | OPRD1KMT2APTPN1 | |
| SCHEMBL30011678 | 0.88 | KMT2A (0.47) | OPRD1TLR2KMT2A | |
| SCHEMBL31217959 | 0.88 | KMT2A (0.47) | OPRD1TLR2KMT2A | |
| SCHEMBL23698366 | 0.88 | KMT2A (0.47) | OPRD1TLR2KMT2A | |
| SCHEMBL27224594 | 0.88 | KMT2A (0.47) | OPRD1TLR2KMT2A | |
| SCHEMBL30129765 | 0.88 | KMT2A (0.47) | OPRD1TLR2KMT2A | |
| SCHEMBL31690598 | 0.88 | PTPN1 (0.41) | OPRD1KMT2APTPN1 | |
| SCHEMBL30918245 | 0.88 | PTPN1 (0.41) | OPRD1KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-4129345-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | CFD, DDOST, HEXD | OPRD1 2630/4885TLR2 1583/4885KMT2A 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.